Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1995-11-13
1999-11-30
Eisenschenk, Frank C.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 5, 435 6, 435 71, 435 691, 4351723, 435239, 436501, 436538, 436811, 935 80, G01N 3353, G01N 33566, G01N 33537
Patent
active
059940832
DESCRIPTION:
BRIEF SUMMARY
DESCRIPTION
The subject of the present invention is a process for the preparation of immunogens or diagnostic reagents that mimic an antigen or a pathogenic organism specific to a disease, even if this is uncharacterized or even unknown (thereby including auto-immune diseases whose etiology and/or pathogenesis is known or unknown). This process is based on the existence and availability of antibodies, both monoclonal or polyclonal, or of serum containing antibodies, which react specifically with the organism causing the infection.
Antibodies suitable for use in this process can be specific for any antigen of interest for which an immunogen or diagnostic reagent that mimes the antigen is sought. The antigen can be a protein or peptide whether synthetic, derived from a natural source, or produced recombinantly; carbohydrate; polysaccharide; glycoprotein; hormone; receptor; antibody; virus; substrate; metabolite; transition state analog; cofactor; drug; dye; nutrient; growth factor; cellular component; oncogene product; bacteria and their extracellular products; mammalian cells and extracts therefrom including tumor cells, virus infected cells and normal cells; parasites; protozoa; malarial antigens; helminths; fungi; rickettsia; or an allergen including but not limited to pollens, dusts, danders or extracts of the same; or a venom, poison, toxin, or toxoid; nucleic acids including DNA; or any other antigen without limitation. Antigens of viruses which are suitable for use in the present invention include antigens from the viruses including but not limited to polio virus, influenza virus, HIV, HTLL, papilloma virus, adeno virus, parainfluenza virus, measles virus, mumps virus, respiratory syncytial virus, shipping fever virus, Western and Eastern encephalomyelitis virus, Japanese B encephalomyelitis virus, Russian spring-summer encephalomyelitis virus, hog cholera virus, hepatitis virus, pox virus, rabies, virus, distemper virus, herpes virus, cytomegalo virus, foot and mouth disease virus, rhinovirus, Newcastle disease virus, vaccinia virus; and pseudorabies virus. The mime can be an immunogen, a vaccine, an inhibitor or activator, etc. without limitation.
As is known, all vaccines and diagnostic reagents currently on sale or undergoing clinical tests are conventionally obtained by means of processes based on the manipulation, modification and/or adaptation of pathogenic organisms or components thereof. These methods have given good results, but are not without problems. The greatest limitation associated with these methods is connected with the fact that they depend upon the availability of information and/or material directly deriving from pathogenic organisms or components thereof.
Previous attempts to overcome the above described limitation have so far failed for a lack of an efficient and reproducible experimental protocol; in particular, these attempts did not provide sufficient information in order to identify and characterize immunogenic mimics to be used for diagnosis and vaccine therapy. It must be emphasized that the present invention is focused on the development of a new technology aimed at overcoming conceptual and technical inadequancies of previously proposed protocols.
A key feature of the present invention is a novel strategy for the selection of antigenic and immunogenic mimics, based on the use, as reagents, of serum samples from patients and a counter-selection step utilizing serum samples from healthy individuals.
Use of the process for preparation according to the present invention allows this limitation to be overcome, furthermore offering additional advantages which will be clear from the following description.
The process for the preparation of immunogens or diagnostic reagents that mimic an antigen or a pathogenic organism specific to a disease--according to the present invention--is essentially characterized by the following operations: pathogenic organism specific to the disease; oligopeptides, expressed from random sequence oligonucleotidic inserts introduced into a gene coding
REFERENCES:
patent: 4751181 (1988-06-01), Keene et al.
patent: 5010175 (1991-04-01), Rutter et al.
patent: 5182366 (1993-01-01), Huebner et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5270170 (1993-12-01), Schatz et al.
patent: 5432018 (1995-07-01), Dower et al.
patent: 5492807 (1996-02-01), Santi et al.
Barbas et al, "Assembly of combinatorial antibody libraries on phage surfs: The gene II site", Proc. Nat. Acad. Sci. USA, 88:7978-7982 (1991).
Brown, S., "Engineered iron oxide-adhesion mutants of Escherichia coli phage .lambda. receptor", Proc. Natl. Acad. Sci. USA, 89:8651-8655 (1992).
Christian et al, "Simplified Methods for Construction, Assessment and Rapid Screening of Peptide Libraries in Bacteriophage", J. Mol. Biol., 227:711-718 (1992).
Folgori et al, "A General Strategy to Identify Mimotopes for Pathological Antigene Using Only Random Peptide Libraries and Human Sera", The EMBO Journal, 13:2236-2243 (1994).
Geysen et al, "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid", Proc. Natl. Acad. Sci. USA, 81:3998-4002 (1984).
Houghten, R., "General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids", Proc. Natl. Acad. Sci. USA, 82:5131-5135 (1985).
Lam et al, "A new type of synthetic peptide library for identifying ligand-binding activity", Nature, 354:82-84 (1991).
Dybwad et al, "Structural Characterization of Peptides That Bind Synovial Fluid Antibodies from RA Patients: A Novel Strategy for Identification of Disease-Related Epitopes Using a Random Peptide Library", Clinical Immunology and Immunopathology, vol. 75, No. 1, pp. 45-50, Apr. 1995.
Edington, S.M., "Shape Space: Is biopharmaceutical discovery entering a new evolutionary stage?", Bio/Technology, vol. 11, pp. 285-289, Mar. 11, 1993.
Devlin et al. Jul. 1990 Science 249 pp. 404-406.
Dybwad et al. Apr. 1993 Eur J Immunol. 23 pp. 3189-3193.
Felici et al. Nov. 1991 J Mol. Biol. 222 pp,. 301-310.
Greenwood et al. Mar. 1991 J Mol Biol 220 pp. 821-827.
Parmley et al. Jan. 1989 Adv. Exp. Med. Biol. pp. 215-218.
Scott et al. Jul. 1992 TIBS 17 pp. 241-245.
Smith et al. Jan. 1993 Methods in Enzymology 217 pp. 228-256.
Scott and Smith Jul. 22, 1990 Science v 249 p. 386.
Cortese Riccardo
Felici Franco
Luzzago Alessandra
Monaci Paolo
Nicosia Alfredo
Eisenschenk Frank C.
Istituto di Recerche di Biologia Molecolare P. Angeletti S.p.A.
Zeman Mary K
LandOfFree
Process for the preparation of immunogens or diagnostic reagents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for the preparation of immunogens or diagnostic reagents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the preparation of immunogens or diagnostic reagents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1670246